Haba Laboratories Inc. said its normalized net income for the fiscal third quarter ended Dec. 31, 2014, amounted to ¥15.73 per share, a decrease of 84.7% from ¥103.11 per share in the year-earlier period.
Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was ¥61.9 million, a decrease of 84.7% from ¥405.6 million in the prior-year period.
The normalized profit margin dropped to 1.7% from 10.1% in the year-earlier period.
Total revenue fell 8.1% year over year to ¥3.69 billion from ¥4.01 billion, and total operating expenses climbed 6.9% year over year to ¥3.58 billion from ¥3.34 billion.
Reported net income declined 65.9% year over year to ¥136.0 million, or ¥34.57 per share, from ¥399.0 million, or ¥101.43 per share.
As of Feb. 16, US$1 was equivalent to ¥118.46.
